An interventional study of Viviscal Oral Supplement Tablets in Hair Thinning, sponsored by Irish Response t/a Lifes2good. Completed at 1 site in United States. Open to participants aged 24 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-14.
Sponsored by Irish Response t/a Lifes2good · Not applicable, Interventional, and Supportive care
The purpose of this multi-site, double-blind, placebo-controlled clinical study, conducted for Lifes2Good, is to evaluate certain physiological effects of Viviscal Oral Supplement compared to a placebo in female subjects with self-perceived thinning hair associated with poor diet, stress, hormonal influences, or abnormal menstrual cycles.
Viviscal is an oral food supplement specifically designed to promote the quality of existing hair growth and/or to promote new hair re-growth for women suffering from temporary thinning hair. It does not contain hormones, drugs, or industry by-products. Viviscal has been marketed in Europe for over 15 years. The key ingredient is AminoMar C - a protein rich compound of marine extracts blended with soluble silica and fortified with Vitamin C. Viviscal provides essential nutrients to nourish hair naturally from within. Viviscal works over several months of use to improve the appearance of thinning hair.
The purpose of this multi-site, double-blind, placebo-controlled clinical study, conducted for Lifes2Good, is to evaluate certain physiological effects of Viviscal Oral Supplement compared to a placebo in female subjects with self-perceived thinning hair associated with poor diet, stress, hormonal influences, or abnormal menstrual cycles. A total of 72 female subjects (36 subjects at the Dallas Research Center and 36 subjects at the Colorado Research Center) completed the study.
At day 0, prior to clinical procedures, subjects were assigned to 1 of the 2 treatment groups, Viviscal Oral Supplement or Placebo Tablets, based on the completely randomized study design that was generated with no input of subject information and conditions. During the course of the study, subjects consumed 1 tablet (512 mg) 3 times per day of the assigned test material, Viviscal Oral Supplement or Placebo Tablets, with water after food.
Clinical evaluations were conducted at visit 1 (day 0), visit 2 (day 2), visit 3 (3 months ± 2 weeks), visit 4 (2 days after visit 3), visit 5 (6 months ± 2 weeks), and visit 6 (2 days after visit 5). Subjects participated in the following procedures at the indicated time points:
609 studies on the registry are indexed under Alopecia; 131 are open to participants now.
This study's enrollment of 96 is above the median of 45 across 513 interventional studies indexed under Alopecia.
Browse Alopecia studies →This is the only study on the registry with Irish Response t/a Lifes2good as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Viviscal Oral Supplement Tablets (as 512mg coated red-brown tablets in unbranded blister packs)
Dietary Supplement: Viviscal Oral Supplement Tablets
Placebo Tablets (as 512 coated red-brown tablets in unbranded blister packs)
Dietary Supplement: Viviscal Oral Supplement Tablets
Tablet (512 mg)
Hair shedding rate
The numbers of scalp hairs shed at month 3 and month 6 when compared with baseline values.
Time frame: 6 months
Hair fiber diameter
Mean vellus hair width change
Time frame: 6 months
Quality of life questionnaires
Quality of life questionnaires relating to perception of quality of hair growth and their wellbeing.
Time frame: 6 months
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.